Delta Lloyd NV acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,088 shares of the medical device company’s stock, valued at approximately $786,000.

Other large investors also recently bought and sold shares of the company. Mn Services Vermogensbeheer B.V. boosted its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in DexCom by 2.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,596 shares of the medical device company’s stock valued at $337,000 after buying an additional 112 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in DexCom by 0.8% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 18,077 shares of the medical device company’s stock valued at $1,532,000 after buying an additional 140 shares during the last quarter. IFP Advisors Inc boosted its stake in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in DexCom by 1.5% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 12,541 shares of the medical device company’s stock valued at $1,063,000 after buying an additional 186 shares during the last quarter.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Shares of DexCom, Inc. (NASDAQ:DXCM) traded down 1.46% on Friday, reaching $67.66. 1,632,226 shares of the company’s stock were exchanged. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $96.38. The stock’s market cap is $5.84 billion. The company’s 50 day moving average price is $75.47 and its 200-day moving average price is $73.57.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06. The firm had revenue of $142.30 million for the quarter, compared to analysts’ expectations of $143.94 million. DexCom had a negative return on equity of 23.61% and a negative net margin of 10.64%. Equities analysts forecast that DexCom, Inc. will post ($0.68) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/delta-lloyd-nv-acquires-shares-of-10088-dexcom-inc-dxcm/1291431.html.

DXCM has been the topic of several recent research reports. B. Riley reaffirmed a “buy” rating and issued a $94.00 target price on shares of DexCom in a research note on Monday, February 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $95.00 target price on shares of DexCom in a research note on Friday, February 10th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of DexCom in a research note on Thursday, April 13th. Northcoast Research reaffirmed a “buy” rating on shares of DexCom in a research note on Wednesday, March 1st. Finally, Jefferies Group LLC raised their target price on shares of DexCom from $80.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, March 1st. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $91.81.

In related news, insider Terrance H. Gregg sold 15,000 shares of the stock in a transaction on Thursday, April 20th. The stock was sold at an average price of $74.10, for a total value of $1,111,500.00. Following the transaction, the insider now directly owns 454,559 shares in the company, valued at approximately $33,682,821.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 8,649 shares of the stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the completion of the transaction, the chief executive officer now owns 347,329 shares in the company, valued at $23,753,830.31. The disclosure for this sale can be found here. Insiders have sold a total of 132,202 shares of company stock worth $10,102,405 over the last 90 days. Company insiders own 2.80% of the company’s stock.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.